Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-<i>trans</i> retinoic acid in acute myeloid leukemia across subtypes
Kimberly N. Smitheman(GlaxoSmithKline (United States)), Helai P. Mohammad(Arysta LifeScience (France))
Cited by 63
Related Papers
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
|Nature Cancer|2021|279
Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma
|Nature Communications|2019|84